Corporate Information And Statement Of Ifrs Compliance [Abstract]

Pharming Group N.V. - Filing #1859781

Concept	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2019-12-31
Corporate information and statement of IFRS compliance [abstract]
Domicile of entity	—	Netherlands	—	—
Legal form of entity	—	limited liability public company	—	—
Address of entity's registered office	—	Darwinweg 24	—	—
Description of nature of entity's operations and principal activities	—	Pharming is a specialty pharmaceutical company developing innovative products for the safe, effective treatment of rare diseases and unmet medical needs. Pharming’s lead product, RUCONEST® (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (“HAE”) attacks in patients in Europe, the US, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.	—	—
Name of ultimate parent of group	—	Pharming Group N.V.	—	—
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [text block]	—	—	—	—
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [abstract]
Disclosure of amounts to be recovered or settled after twelve months for classes of assets and liabilities that contain amounts to be recovered or settled both no more and more than twelve months after reporting date [line items]
Current inventories	27,310,000 USD	—	21,157,000 USD	16,223,000 USD